The EC mapping retains reported palmitoyl-thioester probe hydrolysis, with endogenous protein substrates unresolved.

The PTN001809699 assertions cover membrane location, lysosome organization and glycosyl hydrolase activity. Direct descendant evidence is authenticated separately from uninspected historical ancestral placement.

The membrane vocabulary assignment is refined using direct lysosomal localization and precursor-processing evidence.

The exact mouse donor Q3UMW8 has experimental lumen localization and an acyl-CoA annotation from the same 2022 study; the latter substrate-specific assay remains unresolved.

The cytosol and macromolecule-depalmitoylation implications are assessed separately from their positive transport and catalytic premises.

The combined mouse ortholog, Ensembl, domain and subcellular-location sources support lysosomal localization without representing independent experiments.

This early NCL review presents CLN3 and CLN5 functions as unknown and proposes a shared catabolic context. It does not directly demonstrate a CLN5-performed protein-breakdown reaction.

The authentic abstract describes CLN5 expression in developing human brain and postmitotic migrating neuroblasts. The original subcellular images and additional developmental evidence remain inaccessible.

Patient-cell lysosomal pH is elevated in the tested CLN5 line; the recovered original Discussion leaves direct and indirect mechanisms unresolved.

The authentic abstract reports lysosomal colocalization, glycosylation and secretion of expressed human CLN5 in BHK-21 cells, supporting a soluble lysosomal protein.

Human CLN5 constructs interact with CLN2/TPP1 and CLN3 in cell-free and cellular assays. Antibody and translation-start differences separate lysosomal signals from ER/Golgi precursor signals; the 2002 TPP1 binding assay uses precursor material.

CLN3 targeting-motif mutants retain association with CLN5 in COS-1 coexpression assays; this interaction is distinguished from a requirement for CLN3 lysosomal targeting.

CLN5 is positively identified in MPR-affinity-purified material as a mannose-6-phosphorylated glycoprotein. This is glycan-carriage evidence; the receptor is the recognition reagent, so the assay does not substantiate CLN5 lectin activity.

The paper separates mouse CLN5 fusion-protein binding experiments from human CLN5 localization in HeLa and SH-SY5Y cells. Wild-type and trafficking-defective constructs differ; PPT1 overexpression can rescue mutant CLN5 trafficking without proving the converse.

The original abstract reports maturation and lysosomal targeting of CLN5 itself. The author thesis describes precursor cleavage, glycosylation and trafficking experiments; the source does not establish CLN5 as the enzyme or cofactor performing protein maturation.

CLN5 associates with sortilin, Rab5 and Rab7 in cells. Depletion impairs Rab7 loading, retromer recruitment and receptor recycling, with a rescue comparison; no purified GEF activity or membrane-spanning scaffold mechanism is established.

The actual main Methods describe extracellular-vesicle enrichment from expressed prostatic secretions in urine. The inaccessible supplementary protein table prevents independent verification of the CLN5 target entry.

The authentic abstract distinguishes type-II precursor topology, signal-peptide cleavage and mature luminal membrane association through an amphipathic region. Mutant ER retention is separate from normal lysosomal localization.

Human CLN5 glycosylation mutants distinguish folding, trafficking and stability effects. Wild-type protein localizes with LAMP2 and within enlarged Rab5 endosomes; covalent glycans are not a mannose-binding assay.

The original abstract describes SPPL3 cleavage of a historical 407-residue CLN5 precursor into a soluble lysosomal fragment. CLN5 is the substrate of this cleavage, not the protease.

Exact positive binary-screen records support six CLN5 partners, with tagged and fragment-specific scopes preserved. Systematic retesting and sequence verification strengthen the interaction dataset without assigning physiological context to every pair.

Purified CLN5 and deficient-NPC lysate assays support thioesterase capacity; Figure 5 motivates the authors’ neuronal interpretation, while the Discussion cautions that artificial substrates leave physiological substrate specificity unresolved. The Results/legend differ in NPC species labeling. No CoA-specific assay was verified.

The authentic abstract reports CLN5-mediated BMP formation and cellular LPG/BMP changes. Independent later purified-enzyme work supports a bounded BMP-forming capacity but does not assign S,S-BMP stereoinversion to CLN5.

The original cloning report identifies disease-associated CLN5 and predicts membrane features. Later processing and localization studies qualify the precursor-versus-mature-protein interpretation.

The authentic abstract reports glycoside-hydrolase activity for both Dictyostelium and human CLN5. Exact substrates, purification and specificity controls remain unverified because original full text was not recovered.

The published study directly measures purified CLN5 making R,racemic BMP but not S,S-BMP; PLD3/4 perform the stereoinversion-associated pathway. Its unchanged BMP phenotype after CLN5 deletion is cell-context specific.

CLN5-deficient HEK293 cells retain basal BMP in standard serum but lose most BMP after extended culture with heat-inactivated serum. The study experimentally demonstrates extracellular lipid supply as a modifier of the phenotype.

This 2026 preprint reports reduced labeled-LPG-to-BMP conversion in CLN5-deficient lysosomal lysates and rescue by recombinant human CLN5. It is not peer reviewed and does not resolve product stereochemistry in an isolated-enzyme assay.

Human-cell pulse-chase, endogenous-antibody controls and protease inhibitors establish CLN5 C-terminal processing in acidic compartments. CLN5 is the processed substrate; the responsible cysteine protease remains unidentified.

The authentic mouse knockout abstract reports lysosomal storage material and progressive neural pathology, providing experimental grounding for the curated lysosome-organization premise.

The authentic abstract identifies mouse Cln5 expression and describes soluble lysosomal localization in expression systems, corroborating the exact experimental lumen donor record.